Shionogi announces out-licensing agreement with AMR Centre on COT-143, a humanized monoclonal antibody targeting the PcrV protein of Pseudomonas aeruginosa | More News | News Channels - PipelineReview.com
Shionogi announces out-licensing agreement with AMR Centre on COT-143, a humanized monoclonal antibody targeting the PcrV protein of Pseudomonas aeruginosa | More News | News Channels PipelineReview.com
Shionogi announces out-licensing agreement with AMR Centre on COT-143, a humanized monoclonal antibody targeting the PcrV protein of Pseudomonas ...
Comments
Post a Comment